甲磺酸加贝酯辅助治疗急性胰腺炎的效果分析

Effect Analysis of Gabexate Mesylate in Adjuvant Treatment of Acute Pancreatitis

目的:探讨甲磺酸加贝酯辅助治疗对急性胰腺炎(AP)患者的疗效。方法:将2020年3月—2022年5月我院收治的100例AP患者随机分为实验组和对照组,各50例。对照组予以常规治疗,实验组在对照组基础上予以甲磺酸加贝酯辅助治疗。比较两组症状缓解时间、腹内压、APACHEⅡ评分、血清内毒素、淀粉酶、脂肪酶水平及并发症发生情况。结果:实验组腹痛、腹部压痛、腹胀缓解时间短于对照组(P<0.05);实验组治疗7d的腹内压低于对照组(P<0.05);实验组治疗3d的血清淀粉酶水平低于对照组,治疗7d的血清内毒素、淀粉酶、脂肪酶水平均低于对照组(P<0.05);实验组治疗3d、7d的APACHEⅡ评分低于对照组(P<0.05);两组并发症发生率比较,差异无统计学意义(P>0.05)。结论:甲磺酸加贝酯辅助治疗可促进AP症状改善,降低腹内压,加速恢复,并在减少肠源性感染方面具有潜能,在中重症AP临床治疗中具有应用价值。

Objective:To investigate the efficacy of gabexate mesylate adjuvant therapy in patients with acute pancreatitis(AP).Methods:From March 2020 to May 2022,100 AP patients admitted to our hospital were randomly divided into experimental group and control group,50 cases in each group.The control group was given routine treatment,and the experimental group was treated with gabexate mesylate on the basis of the control group.The symptom relief time,intraabdominal pressure,APACHE I score,serum endotoxin,amylase,lipase levels and complications were compared between the two groups.Results:The remission time of abdominal pain,abdominal tenderness and abdominal distension in the experimental group was shorter than that in the control group(P<0.05).The intra-abdominal pressure of the experimental group was lower than that of the control group(P<0.05).The level of serum amylase in the experimental group was lower than that in the control group on the 3rd day of treatment,and the levels of serum endotoxin,amylase and lipase on the 7th day of treatment were lower than those in the control group(P<0.05).The APACHEⅡscores of the experimental group were lower than those of the control group at 3 days and 7 days after treatment(P<0.05).There was no significant difference in the incidence of complications between the two groups(P>0.05).Conclusion:Gabexate mesylate adjuvant therapy can promote the improvement of AP symptoms,reduce intra-abdominal pressure,accelerate recovery,and has potential in reducing intestinal infection.It has application value in the clinical treatment of moderate and severe AP.